Want to see NAMS full AI Analyst Report?
Top Page
NewAmsterdam Pharma Company
(NASDAQ:NAMS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$28.00
▼(-5.53% Downside)
Action:Reiterated
Date:08/05/26
Overall score reflects weak financial performance (large losses and ongoing cash burn) and bearish technical momentum (price below major moving averages and negative MACD). These are partially offset by a strong, low-debt balance sheet and a notable positive corporate catalyst from EMA backing for obicetrapib, which improves the pipeline risk/reward profile.
Positive Factors
Low leverage & strong equity
Extremely low debt and a sizable equity cushion provide durable financial flexibility for a clinical-stage biotech. This capital structure reduces solvency risk, supports continued trial funding or partnerships, and increases optionality for milestone-driven financing over the next several quarters.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates ongoing funding needs to support trials and operations. Over multiple quarters this elevates dilution or external financing risk, constraining strategic flexibility and making the company dependent on partnerships or equity markets to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage & strong equity
Extremely low debt and a sizable equity cushion provide durable financial flexibility for a clinical-stage biotech. This capital structure reduces solvency risk, supports continued trial funding or partnerships, and increases optionality for milestone-driven financing over the next several quarters.
Read all positive factors
NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.33B
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-88.87%
EPS Growth-35.06%
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding119,537,170
10 Day Avg. Volume986,545
30 Day Avg. Volume1,023,534
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$53.29Price Target Upside79.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.88
Revenue Forecast (FY)$30.41M
NewAmsterdam Pharma Company Business Overview & Revenue Model
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CE...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma does not have publicly available information indicating material recurring revenue from marketed products. Its ability to generate revenue is primarily tied to: (1) collaboration o...
NewAmsterdam Pharma Company Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.12M | 22.50M | 45.56M | 14.09M | 102.69M | 0.00 |
| Gross Profit | 6.56M | 22.44M | 45.56M | 14.09M | 102.69M | 0.00 |
| EBITDA | -254.88M | -242.32M | -241.49M | -176.86M | -22.34M | -41.37M |
| Net Income | -259.50M | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
Balance Sheet | ||||||
| Total Assets | 704.45M | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M |
| Cash, Cash Equivalents and Short-Term Investments | 633.85M | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M |
| Total Debt | 82.00K | 202.00K | 448.00K | 60.00K | 126.00K | 186.51K |
| Total Liabilities | 73.03M | 85.85M | 107.12M | 58.70M | 48.43M | 11.36M |
| Stockholders Equity | 631.42M | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M |
Cash Flow | ||||||
| Free Cash Flow | -143.72M | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
| Operating Cash Flow | -143.46M | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Investing Cash Flow | -34.91M | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 41.68M | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
NewAmsterdam Pharma Company Technical Analysis
Negative
29.64
Price Trends
31.01
Negative
32.11
Negative
33.43
Negative
Market Momentum
-1.31
Positive
33.83
Neutral
50.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 29.64 is above the 20-day moving average (MA) of 28.81, below the 50-day MA of 31.01, and below the 200-day MA of 33.43, indicating a bearish trend. The MACD of -1.31 indicates Positive momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 50.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.
NewAmsterdam Pharma Company Risk Analysis
NewAmsterdam Pharma Company disclosed 92 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewAmsterdam Pharma Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $6.10B | 72.74 | 13.65% | ― | 58.85% | 1646.61% | |
60 Neutral | $8.80B | -14.83 | -69.59% | ― | ― | 1.28% | |
59 Neutral | $6.32B | -13.55 | -43.98% | ― | -100.00% | -33.88% | |
54 Neutral | $3.97B | -7.07 | -94.56% | ― | ― | -203.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.33B | -12.23 | -38.33% | ― | -88.87% | -35.06% |
* Healthcare Sector Average
NAMS
NewAmsterdam Pharma Company
26.67
1.60
6.38%
VKTX
Viking Therapeutics
32.94
-7.09
-17.71%
XENE
Xenon
64.23
26.00
68.01%
KNSA
Kiniksa Pharmaceuticals
77.83
44.45
133.16%
IMVT
Immunovant
41.82
26.60
174.77%
NewAmsterdam Pharma Company Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies
Positive
Jul 24, 2026
On July 24, 2026, NewAmsterdam Pharma and its European partner Menarini Group reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion backing marketing authorization for Ubeslo, ...
Business Operations and StrategyExecutive/Board Changes
NewAmsterdam Pharma Announces COO Transition and Advisory Role
Neutral
Jul 22, 2026
On July 16, 2026, NewAmsterdam Pharma Company N.V. announced that Chief Operating Officer Douglas Kling would resign effective August 14, 2026, to become chief executive officer of another clinical-stage biotech company. The company plans to enter...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
Positive
Jun 3, 2026
On June 2, 2026, NewAmsterdam Pharma held its annual general meeting of shareholders in Amsterdam, where investors approved the 2026 Employee Stock Purchase Plan allowing eligible staff to buy ordinary shares at a 15% discount to the lower market ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.